Biotech firm Mabpharm tests Hong Kong listing
China-based biotechnology firm Mabpharm is looking for the greenlight to list in Hong Kong, having filed a draft IPO prospectus with the city’s stock exchange.
The pre-revenue company focuses on the Chinese market, covering cancers and autoimmune diseases, pursuing research and development for the production of drugs and biosimilars.It has nine monoclonal antibody drugs — treatments that use natural immune system functions to fight diseases — among which are three of its ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com